Aurobindo Pharma Ltd. - Research Center
524804 AUROPHARMA Group (A) BSE data
Results
Statement
More
| Mar ' 25 |
Mar ' 24 |
Mar ' 23 |
Mar ' 22 |
Mar ' 21 |
Equity share capital
| 58.08 |
58.59 |
58.59 |
58.59 |
58.59 |
Share application money
Preference share capital
Reserves & surplus
| 20,476.03 |
19,664.23 |
17,855.58 |
17,058.75 |
15,866.02 |
Secured loans
| 4,625.09 |
2,817.84 |
4,142.57 |
1,818.62 |
3,953.10 |
Unsecured loans
Total
| 25,159.20 |
22,540.66 |
22,056.74 |
18,935.96 |
19,877.71 |
Gross block
| 4,065.39 |
3,941.79 |
6,148.98 |
5,680.29 |
6,685.57 |
Less : revaluation reserve
Less : accumulated depreciation
| 1,728.59 |
1,522.66 |
2,461.48 |
2,094.46 |
2,213.50 |
Net block
| 2,336.80 |
2,419.13 |
3,687.50 |
3,585.83 |
4,472.07 |
Capital work-in-progress
| 87.53 |
132.68 |
239.09 |
225.15 |
734.89 |
Investments
| 15,209.57 |
13,393.44 |
8,221.78 |
6,584.36 |
5,009.93 |
Current assets, loans & advances
| 9,879.16 |
9,208.73 |
12,785.28 |
11,205.61 |
12,972.10 |
Less : current liabilities & provisions
| 2,353.86 |
2,613.32 |
2,876.91 |
2,664.99 |
3,311.28 |
Total net current assets
| 7,525.30 |
6,595.41 |
9,908.37 |
8,540.62 |
9,660.82 |
Miscellaneous expenses not written
Total
| 25,159.20 |
22,540.66 |
22,056.74 |
18,935.96 |
19,877.71 |
Book value of unquoted investments
| 15,209.56 |
13,393.43 |
8,221.77 |
6,584.35 |
4,909.89 |
Market value of quoted investments
| 0.01 |
0.01 |
0.01 |
0.01 |
100.04 |
Contingent liabilities
| 1,329.98 |
2,053.57 |
596.69 |
277.61 |
1,337.36 |
Number of equity sharesoutstanding (Lacs)
| 5808.02 |
5859.39 |
5859.39 |
5859.39 |
5859.39 |